Equine IL-1ra/IL-1F3 Biotinylated Antibody Summary
His26-Gln177
Accession # O18999.1
Applications
Equine IL-1ra/IL-1F3 Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-1ra/IL-1F3
Secreted equine IL-1 receptor antagonist (IL-1ra) is a presumably 22 - 25 kDa glycoprotein produced by variety of cell types that antagonizes IL-1 activity (1 - 3). It is a member of the IL-1 family of proteins that includes IL-1 alpha and IL-1 beta. Although there is little amino acid (aa) identity (< 30%) among the three IL-1 family members, all molecules bind to the same receptors, all show a beta -trefoil structure, and all are believed to have evolved from a common ancestral gene (1 - 4). Equine IL-1ra is synthesized as a 177 aa precursor that contains a 25 aa signal sequence plus a 152 aa mature region. There is one intrachain disulfide bond and one potential N-linked glycosylation site (3, 5, 6). Mature equine sIL-1ra is 78%, 78%, 80%, 82%, and 76% aa identical to mature mouse, human, porcine, canine and bovine IL-1ra, respectively. In human, three non-secreted IL-1ra isoforms have also been identified. It is unknown if such an analogous situation exists in equine. Cells known to secrete IL-1ra include fibroblasts, vascular smooth muscle cells, intestinal columnar epithelium, chondrocytes, macrophages, mast cells, neutrophils and hepatocytes.
There are two type I transmembrane glycoprotein receptors for IL-1ra. The first is the bioactive 80 kDa type I IL-1 receptor (IL-1 RI), and the second is the inert (decoy) 65 kDa type II IL-1 receptor. IL-1ra binding to IL-1 RI competitively blocks IL-1 ( alpha or beta ) binding to the same receptor. This results in receptor ligation without activation (1, 7). The type II IL-1 receptor is inert, and any binding of IL-1ra not only fails to block co-existing IL-1 activity, but may actually potentiate it by removing an IL-1 antagonist. Functionally, all activities attributed to IL-1ra are explained by its role as a competitive inhibitor of IL-1 binding to IL-1 RI (1, 2, 8, 9).
- Arend, W.P. et al. (1998) Annu. Rev. Immunol. 16:27.
- Roux-Lombard, P. (1998) Eur. Cytokine Netw. 9:565.
- Dayer-J-M. (2002) Clin. Exp. Rheumatol. 20(27):S14.
- Eisenberg, S.P. et al. (1991) Proc. Natl. Acad. Sci. USA 88:5232.
- Kato, H. et al. (1997) Vet. Immunol. Immunopathol. 56:221.
- Howard, R.D. et al. (1998) Am. J. Vet. Res. 59:712.
- Dinarello, C.A. (1997) Semin. Oncol. (Suppl 9):S9.
- Irikura, V.M. et al. (2002) J. Immunol. 169:393.
- Arend, W.P. and C. Gabay (2000) Arth. Res. 2:245.
Product Datasheets
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsIsotype Controls
Reconstitution Buffers
Staining Reagents
Supplemental Cell Selection Products
Supplemental ELISA Products
Reviews for Equine IL-1ra/IL-1F3 Biotinylated Antibody
There are currently no reviews for this product. Be the first to review Equine IL-1ra/IL-1F3 Biotinylated Antibody and earn rewards!
Have you used Equine IL-1ra/IL-1F3 Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image